Theriva™ Biologics 将在AACR 2026年会上公布Vcn-01治疗转移性胰腺癌Virage二期B临床试验的补充数据

美股速递
Apr 18

Theriva™ Biologics 宣布,即将在美国癌症研究协会(AACR)2026年年会上展示其候选药物Vcn-01针对转移性胰腺癌的Virage二期B临床试验的额外数据。该演示将提供关于Vcn-01疗效与安全性的最新分析结果。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10